MedTrace Logo

Efficacy of Empagliflozin or Linagliptin as an Alternative to Metformin for Treatment of Polycystic Ovary Syndrome

NCT05200793 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2022-01-21

No results posted yet for this study

Summary

The study aims to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS).

Conditions

  • Polycystic Ovary Syndrome (PCOS)

Interventions

DRUG

Empagliflozin 25 mg

This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)

DRUG

Linagliptin 10 mg

This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)

DRUG

Metformin 1500 mg

This study is to compare the efficacy of Empagliflozin or Linagliptin as an alternative to Metformin for treatment of non-diabetic patients with polycystic ovary syndrome (PCOS)

Sponsors & Collaborators

  • Alexandria University

    lead OTHER

Principal Investigators

  • Hanan N Abdel Hafez, PhD · Professor of Obstetrics and Gynecology, Faculty of Medicine Mansoura University

  • Ahmed I ElMallah, PhD · Professor of Pharmacology and Therapeutics, Faculty of Pharmacy Alexandria University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-07
Primary Completion
2022-07-01
Completion
2022-09-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05200793 on ClinicalTrials.gov